INDVIndivior Plc
$37.52
$0.87
(2.33%)
Closed $38.26
$0.74
(1.93%)
After Hours
EarningsAug 6
Mkt Cap$4.56B
Vol1.64M
Fundamentals
Mkt Cap
$4.56B
Volume
-
52W High
$41.00
52W Low
$13.45
PE Ratio
19.38
Avg. Volume
2.2M
EPS (Annual)
$1.64
Rev/Employee
$1,478,520.29
Earnings
Aug 06
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
Zacks
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.
Zacks
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
Zacks
Here's Why Investors Should Hold on to Teladoc Health Stock for Now
TDOC gains on Integrated Care growth, international expansion and cost cuts, but BetterHelp weakness and ongoing losses remain key challenges.
Zacks
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
Zacks
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.
Zacks
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Zacks
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
ALNY teams up with Inceptive in a deal worth up to $2B, using AI models and proprietary RNAi data to speed drug discovery and improve candidate selection.
Zacks
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
Zacks
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Zacks
<
1
2
...
>